Evidence map›Paper›PMID 39026368›Full record

ArticleEuropean journal of medical research2024

Steady-state pharmacokinetics of lamivudine in end-stage kidney failure persons with detectable and undetectable HIV-1 RNA in peritoneal dialysis effluent.

Teboho Mooko, Feziwe Busiswa Bisiwe, Enkosi Mondleki, Molefi Daniel Morobadi, Perpetual Chikobvu, Martin Munene Nyaga, Asis Bala, Dominique Goedhals, Thabiso Rafaki Petrus Mofokeng, Gabre Kemp and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Teboho MookoDepartment of Internal Medicine (G73), University of the Free State, PO Box 339, Bloemfontein, 9300, South Africa. 2011018955@ufs4life.ac.za.
Feziwe Busiswa BisiweDepartment of Internal Medicine (G73), University of the Free State, PO Box 339, Bloemfontein, 9300, South Africa.
Enkosi MondlekiDepartment of Pharmacology, University of the Free State, Bloemfontein, South Africa.
Molefi Daniel MorobadiDivision of Virology, University of the Free State, Bloemfontein, South Africa.
Perpetual ChikobvuDepartment of Health of the Free State, Bloemfontein, South Africa.
Martin Munene NyagaNext Generation Sequencing Unit and Division of Virology, University of the Free State, Bloemfontein, South Africa.
Asis BalaPharmacology and Drug Discovery Research Laboratory, Division of Life Sciences, Institute of Advanced Study in Science and Technology (IASST), Vigyan Path, Guwahati, Assam, 781035, India.
Dominique GoedhalsDivision of Virology, University of the Free State, Bloemfontein, South Africa.
Thabiso Rafaki Petrus MofokengDepartment of Internal Medicine (G73), University of the Free State, PO Box 339, Bloemfontein, 9300, South Africa.
Gabre KempDepartment of Microbiology and Biochemistry, University of the Free State, Bloemfontein, South Africa.
Kwazi Celani Zwakele NdlovuKidney and Hypertension Research Unit and Division of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenally adjusted lamivudine dosages are effective. However, some of the kidney failure patients managed with lamivudine-containing regimens are failing to suppress HIV in peritoneal dialysis (CAPD) effluent. The steady-state lamivudine pharmacokinetics among these patients was evaluated.

methodsThis overnight open-label pharmacokinetic study enrolled participants living with HIV and managed with CAPD. Lamivudine levels in blood serum and CAPD effluent samples were quantified using liquid chromatography coupled with a mass spectrometer. Pharmacokinetic measures were obtained through non-compartmental analysis.

resultsTwenty-eight participants were recruited with a median antiretroviral (ARV) drug duration of 8 (IQR,4.5-10.5) years and a CAPD duration of 13.3 (IQR,3.3-31.9) months. 14.3% (4/28) had detectable unsuppressed HIV-1 viral load in CAPD effluents. The majority (78,6%,22/28) of participants received a 50 mg dose, while 10.7% (3/28), and another 10.7% (3/28) received 75 mg and 300 mg dosages, respectively. Among those treated with 75 and 300 mg, 66.7% (2/3) and 33.3% (1/3) had detectable HIV-VL in CAPD, respectively. The peritoneal membrane characteristics and CAPD system strengths were variable across the entire study population. Lamivudine exposure was increased in blood serum (50 mg-AUC

conclusionsSteady-state lamivudine pharmacokinetic measures were variable among the entire study population. However, the total lamivudine exposure was within the therapeutic levels.

Indexed as

HIV-1HIV InfectionsKidney Failure, ChronicLamivudinePeritoneal DialysisAdultAnti-HIV AgentsFemaleHumansMaleMiddle AgedRNA, ViralViral LoadAnti-HIV AgentsLamivudineRNA, ViralHIV sheddingKidney failureLamivudinePeritoneal dialysisPeritoneumPharmacokinetics

Identifiers

PMID39026368
PMCPMC11256402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.